TD Cowen Reiterates Hold Rating on Organon & Co. (OGN)

TD Cowen analyst Steve Scala reiterated a Hold rating and $27.00 price target on Organon & Co. (NYSE: OGN).

The analyst commented, "OGN has balanced strengths and risks. Strengths include a differentiated strategy and an experienced management team. Risks include modest existing growth prospects, which necessitate successful BD to deliver on aspirational goals, and prospects largely dependent on one drug (Nexplanon; U.S. patent exp 2027 pending 5-year contraception data)."

For an analyst ratings summary and ratings history on Organon & Co. click here. For more ratings news on Organon & Co. click here.

Shares of Organon & Co. closed at $18.29 yesterday.

You May Also Be Interested In

• U.S. debt tops $40 trillion
• Canada's Competition Bureau moves to block B&G Foods' Green Giant sale
• Silo Pharma acquires software assets from Parkview Consulting for stock